HIGHLIGHTS
- who: Raheem F. H. Al Aameri and colleagues from the University, China have published the research work: Targeting CXCL1 chemokine signaling for treating cisplatin ototoxicity, in the Journal: (JOURNAL)
- what: The authors focused on the neutrophil chemotactic chemokine, CXCL1 which showed significant increases in levels in the cochlea at 24 h . In Figure 4A, the authors show that cisplatin treatment produced significant increases in the expression of CXCR2, CXCR1 and CXCL1 by 2.8 u00b1 0.3, 2.6 u00b1 0.1 and 1.7 u00b1 0.1fold, respectively, by 72 h. The authors show . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.